Warning on biosimilar burden

A higher than usual degree of pharmacovigilance is required when patients are switched to new biosimilar medications, say Australian experts Writing in the latest Australian Prescriber two pharmacy academics have stressed that, in comparison with traditional small-molecule drugs, biosimilars have unique safety considerations. Owing to the diversity in their structural complexity and indications, safety will need